PRIOR AUTHORIZATION CRITERIA

BRAND NAME*
(generic)

CINVANTI (ALL PRODUCTS)
(aprepitant)

EMEND (ALL PRODUCTS)
(aprepitant)

EMEND (ALL PRODUCTS)
(fosaprepitant dimeglumine)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization ***Ref # 77-C***

** Drugs that are listed in the target drug box include both brand and generic and all dosage forms and strengths unless otherwise stated*

FDA-APPROVED INDICATIONS

Cinvanti (aprepitant) injectable emulsion

Cinvanti, in combination with other antiemetic agents, is indicated in adults for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Cinvanti has not been studied for the treatment of established nausea and vomiting.

Emend (aprepitant) capsules and oral suspension

Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Emend for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Emend capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Prevention of Postoperative Nausea and Vomiting (PONV)

Emend capsules are indicated in adults for the prevention of postoperative nausea and vomiting.

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.
- Chronic continuous administration of Emend is not recommended because it has not been studied and because the drug interaction profile may change during chronic continuous use.

Emend (fosaprepitant dimeglumine) for injection
Emend for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the prevention of nausea and vomiting associated with highly or moderately emetogenic chemotherapy AND will be used in combination with other antiemetic agents
  OR
- Emend capsules are being prescribed for the prevention of postoperative nausea and vomiting

Quantity Limits apply.

RATIONALE

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Cinvanti and Emend for Injection are indicated in adults for use in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC) including high dose cisplatin and for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Emend for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high dose cisplatin, and for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Emend capsules, in combination with other antiemetic agents, are indicated in patients 12 years of age and older for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high dose cisplatin, and for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Emend capsules are also indicated for the prevention of postoperative nausea and vomiting. Emend has not been studied for the treatment of established nausea and vomiting.[1-3]

For adults and pediatric patients 12 years of age and older who can swallow oral capsules, for the prevention of nausea and vomiting associated with the administration of HEC or MEC, the recommended oral dosage of Emend capsules is Emend 125 mg 1 hour prior to chemotherapy treatment on Day 1 and 80 mg orally once daily on Days 2 and 3 as part of a regimen that includes a 5-HT3 antagonist with or without a corticosteroid.[2]

For patients who cannot swallow oral capsules, Emend for oral suspension can be used instead of Emend capsules. For pediatric patients 6 months to less than 12 years of age or pediatric and adult patients unable to swallow capsules, the recommended dose of Emend for oral suspension to be administered with a 5-HT3 antagonist, with or without a corticosteroid, for the prevention of nausea and vomiting associated with administration of HEC or MEC is 3 mg/kg orally on Day 1 (maximum dose 125 mg) and 2 mg/kg orally on Days 2 and 3 (maximum dose 80 mg). Dosing of Emend for oral suspension is based on weight, to a maximum of 125 mg on Day 1 and 80 mg on Days 2 and 3. Dosing in pediatric patients less than 6 kg is not recommended. After preparation, the final concentration of Emend for oral suspension is 25 mg/ml.[2]

Emend 150 mg injection is administered on Day 1 only as an infusion over 20 -30 minutes initiated approximately 30 minutes prior to chemotherapy; Emend for injection is not administered on Days 2 and 3. Emend for injection should be administered in conjunction with a corticosteroid and a 5-HT3 antagonist.[3]

The recommended dosage of Cinvanti in adults for the prevention of nausea and vomiting associated with HEC is 130 mg intravenously over 30 minutes approximately 30 minutes prior to chemotherapy on Day 1 only. Cinvanti should be administered in conjunction with dexamethasone and a 5-HT3 antagonist. The recommended dosage of Cinvanti in adults for the prevention of nausea and vomiting associated with MEC is 100 mg administered intravenously over 30 minutes approximately 30 minutes prior to chemotherapy on Day 1 only. Cinvanti should be administered with dexamethasone and a 5-HT3 antagonist. Oral aprepitant 80 mg should be administered on Days 2 and 3.[1]

Patients who receive multiday chemotherapy are at risk for both acute and delayed nausea/vomiting based on the emetogenic potential of the individual chemotherapy agents administered on any given day and their sequence. Acute and delayed emesis may overlap after the initial day of chemotherapy until the last day of chemotherapy. The period of risk for delayed emesis after chemotherapy administration has concluded also depends on the specific regimen and the emetogenic potential of the last chemotherapy agent administered in the regimen. According to the National Comprehensive Cancer Network (NCCN) guidelines, substance P/neurokinin-1 (NK-1) receptor antagonists, such as aprepitant, may be used for multiday regimens that are likely to be moderately or highly emetogenic and associated with significant risk for delayed nausea and emesis. If the oral aprepitant regimen is chosen, limited data exist to support administration of aprepitant on days 4 and 5 after multiday chemotherapy.[6]

The limit is designed to allow for the prevention of acute or delayed onset nausea and vomiting associated with chemotherapy at the recommended dose of Emend or Cinvanti. The limit allows a quantity sufficient for four chemotherapy cycles per month (i.e., one chemotherapy cycle every week).

The recommended oral dosage for the prevention of postoperative nausea and vomiting (PONV) is Emend 40 mg within three hours prior to induction of anesthesia. The safety and effectiveness of Emend have not been established for the prevention of postoperative nausea and vomiting in pediatric patients.[2] Since repeated use of general anesthesia carries inherent risks and patients need time to heal/recover following surgical procedures, the quantity for approval was determined based upon the assumption of an average of at least 30 days between surgical procedures utilizing anesthesia. Emend capsules are the only dosage formulation that is indicated for PONV. Cinvanti is not indicated for PONV. Therefore, this criteria does not provide coverage of Emend suspension, Emend for injection or Cinvanti for the prevention of postoperative nausea and vomiting.

REFERENCES

1. Cinvanti [package insert]. San Diego, CA: Heron Therapeutics, Inc.; November 2017.
2. Emend capsules and oral suspension [package insert]. Whitehouse Station, NJ: Merck and Co., Inc; May 2017.
3. Emend for injection [package insert]. Whitehouse Station, NJ: Merck and Co., Inc; August 2017.
4. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed January 2018.
5. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed January 2018.
6. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemesis. V.2.2017. Available at: www.nccn.org. Accessed January 2018.

Written by:	UM Development (JG)
Date Written:	03/2003 Revised: (MG) 03/2004, 10/2004, 06/2005; (AK) 06/2006, 07/2006; (AM) 04/2007, 11/2007, 04/2008, 03/2009, (KD) 03/2010; (MS) 04/2011, 11/2011 (Updated to comply with CAS Web), 02/2012, 09/2012 (added new 150 mg injection strength), 01/2013, (SE) 07/2013 (created commercial version); (RP) 01/2014, 01/2015; (CT) 05/2015 ((added denial reasons); (KM) 01/2016: 01/2017 (removed contraindication question; reordered questions); 11/2017 (added Cinvanti); 01/2018
Reviewed:	04/2003; 03/2004; Medical Affairs: 10/2004; (MM) 06/2006, 07/2006; (WF) 04/2007, 11/2007, 04/2008, 03/2009, 03/2010; (KP) 04/2011, 02/2012; (LS) 01/2013, (LMS) 07/2013; (KP) 01/2014; (SES) 01/2015; (DHR) 01/2016; (LMS) 01/2017; (JG) 12/2017; (LMS) 01/2018
External Review:	08/2005; 08/2006, 08/2007, 08/2008, 08/2009, 08/2010, 08/2011, 04/2012, 06/2013, 04/2014, 04/2015, 04/2016, 04/2017, 04/2018

CRITERIA FOR APPROVAL

1	Is the requested drug being prescribed for the prevention of nausea and vomiting associated with highly or moderately emetogenic chemotherapy? [If no, then skip to question 3.]	Yes	No
2	Will the requested drug be used in combination with other antiemetic agents? [If yes, then skip to question 5]. [If no, then no further questions.]	Yes	No
3	Is the requested drug being prescribed for the prevention of postoperative nausea and vomiting?	Yes	No
4	Is this request for Emend capsules?	Yes	No
5	Does the patient require use of MORE than any of the following: A) 4 vials per 28 days of Cinvanti, B) 16 capsules per 28 days of Emend 80 mg, C) 4 capsules per 28 days of Emend 125 mg, D) 4 packs per 28 days of Emend Tri-pack, E) 12 kits per 28 days of Emend 125 mg for Oral Suspension, F) 4 vials per 28 days of Emend 150 mg injection, G) 6 capsules per 6 months of Emend 40 mg? [RPh Note: If yes, then deny and enter a partial approval per Limit Criteria Chart.]	Yes	No

Mapping Instructions			
	Yes	**No**	**DENIAL REASONS – DO NOT USE FOR MEDICARE PART D**
1.	Go to 2	Go to 3	
2.	Go to 5	Deny	Your plan covers this drug when you will take this drug with another drug to prevent nausea and vomiting caused by chemotherapy. Your use of this drug does not meet the requirement. This is based on the information we have.
3.	Go to 4	Deny	Your plan covers this drug when you meet one of these conditions: - You have nausea or vomiting from certain types of chemotherapy - You have nausea or vomiting from surgery Your use of this drug does not meet the requirement. This is based on the information we have.
4.	Go to 5	Deny	Your plan covers this drug when you meet all of these conditions: - You have nausea or vomiting from surgery - This request is for Emend capsules Your use of this drug does not meet these requirements. This is based on the information we have.
5.	Deny RPh Note: For the denial verbiage, only include the requested drug. Remove all the other drugs from the verbiage.	Approve, 6 months **See Limit Criteria Chart	You have requested more than the maximum quantity allowed by your plan. Current plan approved criteria cover up to: - 4 vials per 28 days of Cinvanti - 16 capsules per 28 days of Emend 80 mg - 4 capsules per 28 days of Emend 125 mg - 4 packs per 28 days of Emend Tri-pack - 12 kits per 28 days of Emend 125 mg for Oral Suspension - 4 vials per 28 days of Emend 150 mg injection - 6 capsules per 6 months of Emend 40 mg You have been approved for the maximum quantity that your plan covers for a duration of 6 months. Your request for additional quantities of the requested drug and strength has been denied.

LIMIT CRITERIA

Drug	**Quantities to approve**
Cinvanti 130 mg Vial	4 vials / 21 days
Emend 80 mg Capsules	16 capsules / 21 days
Emend 125 mg Capsules	4 capsules / 21 days
Emend Tri-pack (contains one 125 mg capsule and two 80 mg capsules)	4 packs / 21 days
Emend 125 mg for Oral Suspension (Single-Dose Kit)	12 kits / 21 days
Emend 150 mg Injection	4 vials / 21 days
Emend 40 mg Capsule	6 capsules / 6 months

**** This drug is indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit.*** *The duration of 21 days is used for a 28-day fill period.*